Since NF-kB has a ubiquitous role in controlling cytokine activity and immunoregulatory genes, the inhibition of NF-kB activity by steroid hormones, antioxidants, non-steroid anti-inflammatory drugs, and protease inhibitors represents a pharmacological basis for the intervening adjuvant therapy in numerous diseases, including cancer, diabetes mellitus, AIDS, and diverse inflammatory disorders [109]. This evidence concerns the gene NFKB1 and cancer.